The top five holdings in this ETF are: Pfizer Inc (PFE, 5.43% of assets), Sanofi SA ADR (SNY.PA, 5.36%), AstraZeneca PLC ADR (AZN.L, 5.23%), AbbVie Inc (ABBV, 5.06%), and Novo Nordisk A/S ADR (NVO, 5.06%).
VanEck Vectors Pharmaceutical ETF (PPH)
From Successful Investing
Thankfully, it remains entirely possible the Fed is right that inflation is only “transitory.” Sadly though, there has not been a Fed in history that thought it was willingly creating an inflationary problem. Point being, these people are very smart and experienced, but they aren’t perfect.
The bottom line is that over the coming months and quarters, I will have a heightened focus on whether inflation is temporary (or not), and whether the economy is overheating—because frankly, the stakes are high for the remainder of 2021 and well beyond.
Although it got off to an inauspicious start in our portfolios, we’ve seen a precipitous rise in the value of the VanEck Pharmaceuticals ETF since early March. In fact, PPH was up nearly 6% since our last issue.
This is a circumstance that I suspected we would have much sooner than we did; however, sometimes in this business you are right about an idea but either too early or too late in your implementation. Well, turns out we were a bit early on PPH, but now the ETF that holds some of the biggest, and arguably best, pharmaceutical companies in the market is starting to perform as I thought it would.
If you don’t own PPH, I think it’s wise to add it to your Growth Portfolio holdings.
Jim Woods, Successful Investing, CustomerService@JimWoodsInvesting.com, 1-800-211-4766, June 2021